Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
for EGFR Mutation Positive Non-small Cell Lung Cancer
6 locations incl. Calverton
Sponsor: Nuvectis Pharma, Inc.
Sex: All·Age: 18+
Code: NCT07315113·Phase 1·Recruiting·Listed Jan 2026